Dushyant V Sahani
Director of CT, Massachusetts General Hospital · Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dushyant V Sahani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:32 UTC. Open this list on ClinicalTrials.gov
- N/ANCT01825213 · Stratification of Patients With Chronic Liver Disease Using Multi Spectral CTMassachusetts General Hospital · completed · Chronic Liver Disease, HepatoCellular Carcinoma, Liver Fibrosis · principal investigator
- Ph1NCT00621283 · Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric PopulationMassachusetts General Hospital · terminated · Acute Recurrent Pancreatitis, Chronic Pancreatitis · principal investigator
- Ph1NCT00621556 · Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the PancreasMassachusetts General Hospital · terminated · Intraductal Papillary Mucinous Neoplasms · principal investigator
- Ph1NCT00620919 · Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic PancreatitisMassachusetts General Hospital · terminated · Chronic Pancreatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:32 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med · 20041,549 citationsRCR 31.8
- Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.J Clin Oncol · 2009408 citationsRCR 9.3
- 333 citationsRCR 7.0
- 229 citationsRCR 5.5
- Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.Oncologist · 2008134 citationsRCR 3.8
- 128 citationsRCR 4.6
- The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure.AJR Am J Roentgenol · 2008120 citationsRCR 3.4
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.Proc Natl Acad Sci U S A · 2015102 citationsRCR 2.9
- Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.Int J Radiat Oncol Biol Phys · 201172 citationsRCR 1.9
- Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.Clin Cancer Res · 201359 citationsRCR 1.5